Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Use of sulfonamide inhibitors of BCL-2 and BCL-xL to treat ophthalmic disease by selectively removing senescent cells

Use of sulfonamide inhibitors of BCL-2 and BCL-xL to treat ophthalmic disease by selectively removing senescent cells

US Patent 10328073 · Granted Jun 25, 2019

Estimated economic value: $2,770,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Doherty amplifier2025
Doherty amplifier2025
Folding drying rack2025
Bispecific tetravalent antibodies and methods of making and using thereof2025
Guidance and navigation control proteins and method of making and using thereof2025
Roles of modulators of intersectin-Cdc42 signaling in Alzheimer's disease2025
Treatment of a senescence-associated ocular disease or disorder using a Bcl-xL s2025
Treatment of a senescence-associated ocular disease or disorder using a Bcl-xL s2025
Treatment of a senescence-associated ocular disease or disorder using a Bcl-xL s2025
Treatment of a senescence-associated ocular disease or disorder using a Bcl-xL s2025
Treatment of a senescence-associated ocular disease or disorder using a Bcl-xL s2025
Treatment of a senescence-associated ocular disease or disorder using a Bcl-xL s2025